Ratings by Needham (Alan Carr)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/11/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2025 | Pliant Therapeutics | PLRX | Downgrade | Hold (Buy) |
1.38 (1.33) |
-3.62% | Details | |
| 2/10/2025 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/25/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2022 | Vertex | VRTX | Maintain | Hold (Hold) |
|
Details | ||
| 3/1/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2021 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2021 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2021 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2020 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2020 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2020 | Vaxcyte | PCVX | New Coverage | Buy (N/A) |
29.38 (59.29) |
101.8% | Details | |
| 6/30/2020 | Intercept Pharmaceuticals | ICPT | Maintain | Buy (N/A) |
|
Details | ||
| 6/29/2020 | Pliant Therapeutics | PLRX | New Coverage | Buy (N/A) |
31.72 (1.33) |
-95.81% | Details | |
| 4/8/2020 | Nabriva Therapeutics AG | NBRV | Downgrade | Hold (Buy) |
0.56 (1.42) |
153.57% | Details | |
| 3/5/2020 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | Moderna | MRNA | Maintain | Hold (N/A) |
|
Details | ||
| 11/19/2019 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2019 | Phathom Pharmaceuticals | PHAT | New Coverage | Buy (N/A) |
24.27 (10.67) |
-56.04% | Details | |
| 11/15/2019 | Zealand Pharma A/S | ZEAL | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2019 | Zealand Pharma A/S | ZEAL | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2019 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2019 | Vertex | VRTX | Downgrade | Hold (Buy) |
169.54 (456.69) |
169.37% | Details | |
| 7/23/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2019 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2019 | Tricida | TCDA | New Coverage | Buy (N/A) |
37.57 (0.11) |
-99.71% | Details | |
| 5/8/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2019 | Nabriva Therapeutics AG | NBRV | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2019 | Neurocrine Bio. | NBIX | Downgrade | Hold (Buy) |
91.28 (95.51) |
4.63% | Details | |
| 1/24/2019 | Intercept Pharmaceuticals | ICPT | Upgrade | Buy (Hold) |
110.93 (19.00) |
-82.87% | Details | |
| 1/2/2019 | Moderna | MRNA | New Coverage | Buy (N/A) |
15.27 (52.52) |
243.94% | Details | |
| 12/12/2018 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 11/30/2018 | CRISPR Therapeutics | CRSP | New Coverage | Buy (N/A) |
37.62 (56.50) |
50.19% | Details | |
| 11/7/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2018 | Nabriva Therapeutics AG | NBRV | Maintain | Buy (N/A) |
|
Details | ||
| 10/12/2018 | Trevena | TRVN | Downgrade | Hold (Buy) |
0.95 (2.50) |
163.16% | Details | |
| 9/18/2018 | Zealand Pharma A/S | ZEAL | Maintain | Buy (N/A) |
|
Details |
